/

Società

Az

Non verificato

Azafaros

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

7 comunicati stampa

Guarda tutti i comunicati

08/01/2026

Scienza

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

Eventi

Industria

Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference

Fonte

Emittente

1.00

0

11/12/2025

Mercato del lavoro

Scienza

Igiene alimentare

Biotecnologia

Medicina - Varie

Salute

Farmaceutica

Azafaros Further Strengthens Its Board of Directors With Appointment of Biotech Entrepreneur Dr. Thierry Abribat

Fonte

Emittente

1.00

0

28/07/2025

Scienza

Infanzia

Medicina - Varie

Biotecnologia

Farmaceutica

Vetrine/Shopping

Salute

Industria

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively

Fonte

Emittente

1.00

0

09/06/2025

Scienza

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

Fiere

Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing

Fonte

Emittente

1.00

0

13/05/2025

Mercato del lavoro

Biotecnologia

Farmaceutica

Finanza

Sanità

Salute

Associazioni/Professionisti

Medicina - Varie

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders

Fonte

Emittente

1.00

0

09/01/2025

Eventi

Industria

Biotecnologia

Farmaceutica

Medicina alternativa

Salute

Igiene alimentare

Medicina - Varie

Sanità

Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

Fonte

Emittente

1.00

0

10/09/2024

Eventi

Industria

Scienza

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0